Clostridium difficile infection in patients with inflammatory bowel disease

Annals of Gastroenterology

Volumn 24, Issue 4, 2011, Pages 263-270

  Saidel Odes, Lisa ^a   Borer, Abraham ^a   Odes, Selwyn ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Clostridium difficile; Crohn's disease; Ulcerative colitis

Indexed keywords

BACITRACIN; FIDAXOMICIN; FUSIDIC ACID; IMMUNOGLOBULIN G; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENTERITIS; ENZYME IMMUNOASSAY; FECES ANALYSIS; HIGH RISK PATIENT; HUMAN; ILEITIS; INFECTION PREVENTION; INFECTION RISK; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; ULCERATIVE COLITIS;

EID: 81255188804     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996 to 2003. Emerg Infect Dis 2006;12:409-415.
2. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-1940.
3. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-344.
4. Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 2009;104:1298-1313.
5. Ricciardi R, Ogilvie JW Jr, Roberts PL, Marcello PW, Concannon TW, Baxter NN. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum 2009;52:40-45.
6. Sonnenberg A. Similar geographic variations of mortality and hospitalization associated with IBD and Clostridium difficile colitis. Inflamm Bowel Dis 2010;16:487-493.
7. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1543-1450.
8. Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg 2007;11:138-142.
9. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008;57:205-210.
10. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010;55:415-420.
11. Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004;38:772-775.
12. Butala P, Divino CM. Surgical aspects of fulminant Clostridium difficile colitis. Amer J Surg 2010;200:131-135.
13. Shen B, Remzi FH, Fazio VW. Fulminant Clostridium difficileassociated pouchitis with a fatal outcome. Nat Rev Gastroenterol Hepatol 2009;6:492-495.
14. Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg 2007;11:138-142.
15. Kurtz LE, Yang SS, Bank S. Clostridium difficile-associated small bowel enteritis after total proctocolectomy in a Crohn's disease patient. J Clin Gastroenterol 2010;44:76-77.
16. Tsironi E, Irving PM, Feakins RM, Rampton DS. "Diversion" colitis caused by Clostridium difficile infection: report of a case. Dis Colon Rectum 2006;49:1074-1077.
17. Morinville V, McDonald J. Clostridium difficile-associated diarrhea in 200 Canadian children. Can J Gastroenterol 2005;19:497-501.
18. Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009;154:854-858.
19. Kelly PK, Lamont JT. Antibiotic-associated diarrhoea, pseudeomembranous enterocolitis, and Clostridium difficileassociated diarrhea and colitis. In: Feldman M, Friedman LS, Brandt LJ (editors): Sleisenger and Fordtran's Gastrointestinal and liver disease, 9th ed. Saunders: Philadelphia, 2010: 1889-1903.
20. Diggs NG, Surawicz CM. Evolving concepts in Clostridium difficile colitis. Curr Gastroenterol Rep 2009;11:400-405.
21. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009;30:253-264.
22. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008;179:767-772.
23. Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009;44:74-78.
24. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-455.
25. Ticehurst JR, Aird DZ, Dam LM, Borek AP, Hargrove JT, Carroll KC. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006;44:1145-1149.
26. Reller ME, Lema CA, Perl TM, et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007;45:3601-3605.
27. Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol 2008;46:1996-2001.
28. Markowitz JE, Brown KA, Mamula P, Drott HR, Piccoli DA, Baldassano RN. Failure of single-toxin assays to detect Clostridium difficile infection in pediatric inflammatory bowel disease. Am J Gastroenterol 2001;96:2688-2690.
29. Deshpande A, Pasupuleti V, Patel P, et al. Repeated stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield. Clin Gastroenterol Hepatol 2011;9:665-669.
30. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011;8:17-26.
31. Balamurugan R, Balaji V, Ramakrishna BS. Estimation of faecal carriage of Clostridium difficile in patients with ulcerative colitis using real time polymerase chain reaction. Indian J Med Res 2008;127:472-7.
32. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009;15:1067-1079.
33. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007;18:CD004610.
34. Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, Rossignol JF. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-427.
35. Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 2010;11:1569-1578.
36. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009;53:261-263.
37. Cornely OA, Miller M, Louie T, Crook D, Sears P, Gorbach SL. Randomized clinical trial (RCT) of fidaxomicin (FDX) versus vancomycin in treatment of recurrent Clostridium difficile infection (CDI). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA. 2010;Abstract L1-1305.
38. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008;23:CD004611.
39. Aas J, Gesset CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infec Dis 2003;36:580-585.
40. Gustafsson A, Lund-Tonnesen S, Berstad A, Midtvedt T, Norin E. Faecal short-chain fatty acids in patients with antibioticassociated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol 1998;33:721-727.
41. Louie TJ, Louie MR, Krulicki W, Byrne B, Ward L. Home-based fecal flora infusion to arrest multiply-recurrent clostridium difficile infection (CDI). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America meeting. Washington, DC, USA. 2008; Abstract K-4201.
42. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;53:882-884.
43. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366-370.
44. Yangco BG, Johnson JG. Single Dose Intravenous Immunoglobulin for the Treatment of Severe Clostridium difficile Colitis. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA 2010; Abstract L1-1748.
45. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
46. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128:764-70.
47. Villano SA, Tatarowicz W, Seiberling M, Gerding DA, Gomez A, Monnot-Chase E. Phase 1 evaluation of an oral suspension of VP 20621, spores of a non-toxigenic C. difficile strain (NTCD), 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, USA. 2010; Abstract F1-2127b.
48. McNulty C, Logan M, Donald IP, Ennis D, Taylor D, Baldwin RN, Bannerjee M, Cartwright KA. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997;40:707-711.
49. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003;24:699-706.
50. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficileassociated diarrhea: a systematic review. CMAJ 2005;173:167-170.
51. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-349.
52. Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol 2010;16:4892-4904.